Literature DB >> 6341226

Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine.

K Matsumoto, T Otani, T Une, Y Osada, H Ogawa, I Azuma.   

Abstract

Stimulation of resistance to infection induced by the analogs of muramyl dipeptide (MDP) having substituted functions in the gamma-carboxyl group of D-isoglutamyl residue was examined in experimental Escherichia coli infections in mice. An MDP analog which is an efficient strengthener of resistance to infection, N alpha-MDP-N epsilon-stearoyllysine [MDP-Lys(L18)], was selected through the comparative assessment of a number of compounds in three categories: (i) gamma-alkylamides, (ii) gamma-esters, and (iii) N alpha-MDP-N epsilon-acyllysine derivatives. Furthermore, the antiinfectious activity of MDP-Lys(L18) was evaluated bacteriologically in comparison with that of MDP. The effect of MDP-Lys(L18) on the susceptibility of mice to infections with various species of microorganisms was studied. Protective activity was greatest against E. coli and staphylococcal infections, considerable against Pseudomonas and Candida infections, and least against Klebsiella infection. The effects of bacterial inoculum size and MDP treatment timing, dose, and route of administration on protective activity were studied. The efficacy of MDP-Lys(L18) in protection tests was demonstrated for all administration routes, even the oral. Its high potency was confirmed by the smaller influence of inoculum size and particularly small value of the minimum dosage required for inducing protective activity. A decrease in bacterial survival was observed in the blood and organs of mice treated with the analog and infected with E. coli. The following two useful effects were obtained: the synergistic effect of glycopeptide and chemotherapeutic agents and the stimulation of resistance to infection in animals immunocompromised by cyclophosphamide treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341226      PMCID: PMC348060          DOI: 10.1128/iai.39.3.1029-1040.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Immunoadjuvant activities of peptidoglycan subunits from the cell walls of Staphyloccus aureus and Lactobacillus plantarum.

Authors:  S Kotani; Y Watanabe; T Shimono; F Kinoshita; T Narita
Journal:  Biken J       Date:  1975-06

2.  Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers.

Authors:  A Adam; M Devys; V Souvannavong; P Lefrancier; J Choay; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1976-09-07       Impact factor: 3.575

3.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

4.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

5.  Splenic modifications induced by cyclophosphamide in C3H/He, nude, and "B" mice.

Authors:  J P Kolb; M F Poupon; G M Lespinats; D Sabolovic; F Loisillier
Journal:  J Immunol       Date:  1977-05       Impact factor: 5.422

6.  Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs.

Authors:  L Chedid; M Parant; F Parant; P Lefrancher; J Choay; E Lederer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

7.  Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds.

Authors:  I Azuma; K Sugimura; T Taniyama; M Yamawaki; Y Yamamura
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

8.  Cellular elements in the resistance to candida infection in mice. I. Contribution of T lymphocytes and phagocytes at various stages of infection.

Authors:  T Miyake; K Takeya; K Nomoto; S Muraoka
Journal:  Microbiol Immunol       Date:  1977       Impact factor: 1.955

9.  Enhancement of non-specific resistance to Pseudomonas pneumonia by a synthetic derivative of muramoyl dipeptide in immunosuppressed guinea pigs.

Authors:  Y Osada; T Ohtani; T Une; H Ogawa; K Nomoto
Journal:  J Gen Microbiol       Date:  1982-10

10.  Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.

Authors:  S Kotani; Y Watanabe; F Kinoshita; T Shimono; I Morisaki
Journal:  Biken J       Date:  1975-06
View more
  15 in total

1.  Synergistic induction of cytotoxicity in macrophages by murine interferon-gamma and biological response modifiers derived from microorganisms.

Authors:  S Nagao; K Sato; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 2.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

3.  Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice.

Authors:  O Tatara; C Nakahama; Y Niki
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Activity of cyclooxygenase-2 and nitric oxide in milk leucocytes following intramammary inoculation of a bio-response modifier during bovine Staphylococcus aureus subclinical mastitis.

Authors:  U K De; Reena Mukherjee
Journal:  Vet Res Commun       Date:  2014-05-21       Impact factor: 2.459

5.  Induction of protective immunity to monoclonal-antibody-defined Plasmodium falciparum antigens requires strong adjuvant in Aotus monkeys.

Authors:  W A Siddiqui; L Q Tam; S C Kan; K J Kramer; S E Case; K L Palmer; K M Yamaga; G S Hui
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

6.  Role of resident macrophages, peripheral neutrophils, and translymphatic absorption in bacterial clearance from the peritoneal cavity.

Authors:  D L Dunn; R A Barke; N B Knight; E W Humphrey; R L Simmons
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Enhancement of resistance to Escherichia coli infection in mice by dihydroheptaprenol, a synthetic polyprenol derivative.

Authors:  S Araki; K Kagaya; K Kitoh; M Kimura; Y Fukazawa
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

8.  Effect of free or liposome-encapsulated muramyl dipeptide on uptake and intracellular survival of Listeria monocytogenes in mouse peritoneal macrophages in vitro.

Authors:  I A Bakker-Woudenberg; A F Lokerse; J C Vink-van den Berg; F H Roerdink
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

9.  Augmentation of protective and antibacterial activity induced by muramyl dipeptides in CBA/N defective mice with X-linked immunodeficiency for Salmonella enteritidis infection.

Authors:  K Onozuka; T Saito-Taki; M Nakano
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

10.  Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.